Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
about
The HIV antiretroviral drug efavirenz has LSD-like propertiesUntangling the Gordian knot of HIV, stress, and cognitive impairmentPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsEfavirenz and the CNS: what we already know and questions that need to be answeredDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialEvolutionary dynamics of HIV at multiple spatial and temporal scales.Neurological and psychiatric adverse effects of antiretroviral drugs.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.HIV-associated neurocognitive disorders: perspective on management strategiesInfluence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patientsProtein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.Etravirine in CSF is highly protein boundAntiretroviral bioanalysis methods of tissues and body biofluids.Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.CSF penetration by antiretroviral drugs.Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.[Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.CNS penetration of ART in HIV-infected children.Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.The Rise and Fall of Efavirenz.
P2860
Q24608183-0E26EC34-39BD-4C8E-8B18-06BB478201B3Q28067483-C7DBA7BF-9B8D-4A0E-BC2A-266F7A15C078Q28069383-CBDED3E8-0DA4-412D-AB87-AE556AC0C9A2Q28085028-DBEDC959-56DA-4308-A2B9-7C90C572890AQ28486428-853CBA2A-614A-40E5-9E9D-E11F372C1449Q28552729-58DA3655-357B-4625-B724-468D60BA42A7Q30416280-A31C6485-FD15-4A56-B74C-EEA5BB5E2FE6Q34039419-A056E555-C1E5-4DD2-8DE5-CB3CDCC1E070Q34202181-13525763-D1D4-4F93-9054-CB71642CF3BDQ34652590-3885B885-90D0-4471-8534-68D8F50E6362Q34756398-FA5FF62A-2A49-476D-A248-CD69A60EBAF7Q36204440-DD1BE7A8-74A5-4C7D-9271-A11B3879D261Q36374300-4F598770-408B-4A00-ADF4-4B52DD9EDA22Q36406259-21746DD6-7CAF-4887-90E9-5C5D6870815AQ36573340-26730A68-BEA8-4E71-B544-1305CB9B76FCQ36664960-7D6F02A3-D142-4E52-B702-AAA53E31A1EDQ36667153-D728ABEA-ECAE-4135-981C-A42D105A88D5Q36762988-09A2BCC5-EE86-42B1-8A31-242A4995DA7DQ37332868-08AE54A9-CA26-4C01-AE1D-FFC0EB307AFEQ37538717-02CDAE7C-6C12-4033-9582-AFFFE5A0BBD5Q37966663-A79C3C5A-DE05-47B7-ACE8-DEA468E89192Q38060571-2B10B61E-A961-40F9-BF3A-2691D86E14F2Q38210096-0F291096-7894-41EE-BB0C-5F4DAC24CEF2Q38247035-D2790376-029B-4F71-A188-C7F029C96FACQ38706868-B6E4DBC0-09A7-482E-85CF-4AE76F2B2AA8Q38990321-DF646344-D164-4D36-987B-30554EA475E4Q39004638-B35C4463-98C6-41EF-B262-CD1185D230A6Q39064765-78AF8142-D3F4-423A-BEDF-C2465F886C8DQ41033215-9CFC1A6E-5158-41F9-8002-2E3D4543937EQ41208022-4C5C0C40-215A-484E-B31A-FFFE31D0F6E0Q41451997-D8071A76-9CB6-433F-858B-0B0958213F51Q41602074-4AF5CB63-0570-48B3-9278-EE0E3454263CQ41748068-230E2C17-6CD2-4268-9EFB-AB1B1AC1A7CAQ42237457-8536A053-B687-4ED1-B1CF-F71D561A7DB5Q42281323-B50D1C9A-F465-4202-AE04-E7E5A0C8E2FDQ42592784-A513A3EE-A22B-4299-891B-47382E37436DQ43419116-FC0158C8-62CB-46EE-91BE-823C441E2D0FQ47416079-39544C38-62D1-4CDC-81C4-56FE087D328DQ47817799-47DD5E77-5FE2-43E9-A2F0-59BCF1DF3B8CQ54665423-9869DA02-8E6A-401A-BEE2-928841AAC970
P2860
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@ast
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@en
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@nl
type
label
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@ast
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@en
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@nl
prefLabel
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@ast
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@en
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@nl
P2093
P2860
P50
P356
P1476
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
@en
P2093
Ann C Collier
Benjamin B Gelman
Brookie M Best
David B Clifford
David M Simpson
Edmund V Capparelli
Gilbert Mbeo
J Allen McCutchan
Peter P Koopmans
Richard Haubrich
P2860
P304
P356
10.1093/JAC/DKQ434
P407
P577
2010-11-23T00:00:00Z